PBS listing of RINVOQ® (upadacitinib) for severe atopic dermatitis
AbbVie announced on 22 January 2022 that RINVOQ® (upadacitinib), a Janus Kinase 1 (JAK1) inhibitor, has been listed on the Pharmaceutical Benefits Scheme (PBS) for Australian patients living with severe atopic dermatitis (eczema), which can affect their whole body, face or hands.
Atopic dermatitis is a chronic inflammatory skin condition caused by an overactive immune system and is one of the most common and severe forms of eczema. Approximately 1.6 million Australians are thought to be living with atopic dermatitis, with around one in five of these suffering from a moderate to severe form of the condition.
Atopic dermatitis has a significant impact on quality of life. As there is no cure for atopic dermatitis, the main goals in managing the disease are to reduce itch, minimise rash, and limit the impact on quality of life. Access to targeted therapies such as RINVOQ® (upadacitinib) provides additional treatment options to help alleviate the burden of this chronic condition.
More information:
www.abbvie.com.au/media/rinvoq-eczema-atop-derm-pbs-listed.html
www.allergy.org.au/patients/skin-allergy
This news item was issued on 1 February 2022 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.
